EUVIMEDEUVIMED entdecken
Open Access

Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment

Leonard A Sowah iD, Laura Smeaton, Irena Brates, Debika Bhattacharya, Benjamin Linas, Bruce Kreter, Sandra Wagner-Cardoso, Sunil Solomon, Mark Sulkowski, Gregory K Robbins

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Leonard A Sowah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Therapeutic Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With the advent of efficacious oral direct-acting antivirals (DAAs) for hepatitis C virus (HCV), identification of characteristics associated with adherence is critical to treatment success. We examined correlates of sub-optimal adherence to HCV therapy in a single-arm, multinational, clinical trial.

Methods

ACTG A5360 enrolled HCV treatment-naive persons without decompensated cirrhosis from 5 countries. All participants received a 12-weeks course of sofosbuvir/velpatasvir at entry. In-person visits occurred at initiation and week 24, sustained virologic response (SVR) assessment. Adherence at week 4 was collected remotely and was dichotomized optimal (100%, no missed doses) versus sub-optimal (<100%). Correlates of sub-optimal adherence were explored using logistic regression.

Results

In total, 400 participants enrolled; 399 initiated treatment; 395/397 (99%) reported completing at week 24. Median age was 47 years with 35% female. Among the 368 reporting optimal adherence at week 4 SVR was 96.5% (95% confidence interval [CI] [94.1%, 97.9%]) vs 77.8% (95% CI [59.2%, 89.4%]) P value < .001. In the multivariate model age <30 years and being a US participant were independently associated with early sub-optimal adherence. Participants <30 years were 7.1 times more likely to have early sub-optimal adherence compared to their older counterparts.

Conclusions

Self-reported optimal adherence at week 4 was associated with SVR. Early self-reported adherence could be used to identify those at higher risk of treatment failure and may benefit from additional support. Younger individuals <30 years may also be prioritized for additional adherence support. Clinical Trials Registration. NCT03512210.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicHepatitis CHumansFemaleMiddle AgedAdultMaleSofosbuvirAntiviral AgentsTreatment OutcomeSustained Virologic ResponseHepacivirusGenotypeBenzimidazolesBenzopyransCarbamatesHeterocyclic Compounds, 4 or More Rings

Stichwörter der Autor:innen

adherencehealth system capacityhepatitis Cminimum monitoringremote patient contact

Substanzen

SofosbuvirAntiviral AgentsvelpatasvirBenzimidazolesBenzopyransCarbamatesHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Therapeutic Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA.
  • Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, Massachusetts, USA.
  • David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
  • Boston University School of Medicine, Boston, Massachusetts, USA.
  • Gilead Sciences Inc, Foster City, California, USA.
  • Instituto Nacional de Infectologia-Laboratorio de Pesquisa Clínica em HIV/AIDS, Rio de Janeiro, Brazil.

ORCID-Profile: Leonard A Sowah

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • NCATS NIH HHS
  • NIDA NIH HHS
  • National Institutes of Health
  • National Institute of Drug Abuse

Zitieren

APA

Sowah, L. A., Smeaton, L., Brates, I., Bhattacharya, D., Linas, B., Kreter, B., Wagner-Cardoso, S., Solomon, S., Sulkowski, M., & Robbins, G. K. (2023). Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad034

Vancouver

Sowah LA, Smeaton L, Brates I, Bhattacharya D, Linas B, Kreter B, et al. Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad034

BibTeX
@article{Sowah2023,
  author = {Sowah, Leonard A and Smeaton, Laura and Brates, Irena and Bhattacharya, Debika and Linas, Benjamin and Kreter, Bruce and Wagner-Cardoso, Sandra and Solomon, Sunil and Sulkowski, Mark and Robbins, Gregory K},
  title = {Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad034}
}
Kostenlos starten →